Trial Information

Summary: The purpose of this study is to determine if the study drug (an investigational blood-thinning medication) is as good as warfarin (Coumadin®) in reducing the formation of blood clots in the hearts of patients with atrial fibrillation.

This clinical research study is for adults 18 years and older who have been diagnosed with atrial fibrillation (a type of irregular heartbeat also known as an arrhythmia) and who need treatment with blood-thinning medication because of an increased risk of blood clotting.

All participants in the study will receive blood-thinning medication; half will take warfarin (Coumadin®), while the other half will take the investigational medication. Neither the study team nor you will know which group you have been assigned - this is known as a double-blind study. The group you are assigned to will be determined at random by a computer, and not the study doctor.

You will generally be required to visit the study site once a month, but possibly more frequently when the study doctor considers this necessary. It is anticipated that, for most study participants, study duration will be around 2-3 years, but it could be slightly more or less. The study team will explain the reasons for this to you at your first visit.

All study related visits, exams and medication will be provided at no cost. Compensation may be provided for study-related travel. Participation is voluntary and you may withdraw from the study at any time.

For more information, click this link:
www.AtrialFibrillationStudy.com/ctw3

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:30:43 AM